Clinical commissioning policy: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Document first published:
Page updated:
Topic:
Publication type:

Obinutuzumab is not recommended to be available as a routine commissioning treatment option in refractory systemic lupus erythematosus (SLE) within the criteria set out in this document.

Document

Clinical commissioning policy: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical commissioning policy: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 155 KB
  • 7 pages

Document

Clinical panel report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical panel report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 86 KB

Document

Clinical priorities advisory group report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical priorities advisory group report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 188 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Equality and Health Inequalities Impact Assessment (EHIA): obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 186 KB

Document

Engagement report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Engagement report: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 159 KB

Document

Evidence review: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Evidence review: obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 372 KB